213 related articles for article (PubMed ID: 28771787)
1. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen CY; Zhou Y; Cui YM; Yang T; Zhao X; Wu Y
J Clin Pharm Ther; 2019 Apr; 44(2):300-311. PubMed ID: 30636182
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy: Model-based dose optimization.
Wu W; Yang WS; Xu XY; Ge XL; Lu J; Wang GF; Wang Y; Li ZP
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):712-726. PubMed ID: 38506371
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Lin WW; Li XW; Jiao Z; Zhang J; Rao X; Zeng DY; Lin XH; Wang CL
Eur J Clin Pharmacol; 2019 Mar; 75(3):381-392. PubMed ID: 30456415
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Li X; Wei S; Wu H; Zhang Q; Zhao Z; Mei S; Feng W; Wu Y
Eur J Pediatr; 2023 Oct; 182(10):4509-4521. PubMed ID: 37493972
[TBL] [Abstract][Full Text] [Related]
8. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?
Di Girolamo G; Opezzo JA; Schere D; Gonzalez CD; Moncalvo JJ
Expert Opin Pharmacother; 2007 Jul; 8(10):1415-23. PubMed ID: 17661724
[TBL] [Abstract][Full Text] [Related]
9. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Peng J; Zhang HN; Liu ZS; Xu H; Wang Y
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):684-92. PubMed ID: 24887335
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
Viola MS; Bercellini MA; Saidón P; Rubio MC
Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents.
Sinha J; Karatza E; Gonzalez D
CPT Pharmacometrics Syst Pharmacol; 2022 Feb; 11(2):225-239. PubMed ID: 34816634
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
Yu Y; Zhang Q; Xu W; Lv C; Hao G
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug interactions in children taking oxcarbazepine.
Sallas WM; Milosavljev S; D'souza J; Hossain M
Clin Pharmacol Ther; 2003 Aug; 74(2):138-49. PubMed ID: 12891224
[TBL] [Abstract][Full Text] [Related]
16. Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.
Clemens PL; Cloyd JC; Kriel RL; Remmel RP
Clin Drug Investig; 2007; 27(4):243-50. PubMed ID: 17358096
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.
Wang Y; Zhang HN; Niu CH; Gao P; Chen YJ; Peng J; Liu MC; Xu H
Acta Pharmacol Sin; 2014 Oct; 35(10):1342-50. PubMed ID: 25220641
[TBL] [Abstract][Full Text] [Related]
18. A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
Rodrigues C; Chhun S; Chiron C; Dulac O; Rey E; Pons G; Jullien V
Eur J Clin Pharmacol; 2018 Jun; 74(6):793-803. PubMed ID: 29564480
[TBL] [Abstract][Full Text] [Related]
19. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
